Genmab — Maj 2025
-
Efter min mening er det absolut ikke timingen at udskifte Winkel. Ikke af forretningsmæssige grunde. Kan ikke få øje påfordelene. Men! Det kommer naturligvis indenfor en forholdsvis kort horisont - grundet alder og fornuft. Kender kan sagtens gå et par år, og sagtens flere.
-
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) https://proinvestor.com/investornyt/1311332/genmab-to-submit-supplemental-biologics-license-application-sbla-to-us-food-and-drug-administration-for-epcoritamab-plus-rituximab-and-lenalidomide-r2-in-patients-with-relapsed-refractory-follicular-lymphoma-fl
-
Genmab håber på udvidet brug af kræftmiddel: Er på vej med ny ansøgning til myndighederne https://proinvestor.com/investornyt/1311364/genmab-haber-pa-udvidet-brug-af-kraeftmiddel-er-pa-vej-med-ny-ansogning-til-myndighederne
-
Dr Lee likes talking about Rina-S... -Dr Lee on the Mechanism of Action of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer https://www.onclive.com/view/dr-lee-on-the-mechanism-of-action-of-rina-s-in-fr-platinum-resistant-ovarian-cancer
-
AMGEN QUARTER 1 2025 TEPEZZA
(teprotumumab-trbw) sales decreased 10% year-over-year to $381 million in the first quarter, primarily driven by 9% lower volume and 8% from a decrease in inventory levels, partially offset by higher net selling price. https://investors.amgen.com/news-releases/news-release-details/amgen-reports-first-quarter-2025-financial-results -
AMGEN Q1 presentation
https://investors.amgen.com/static-files/418d975b-d793-4a44-bb3e-2bc44021ba68 -
We developed a custom AI radiomic biomarker for acasunlimab - Molecular profiling of NSCLC patients associates CT-based radiomic features with signaling pathways indicating a favorable tumor microenvironment for treatment with immunotherapy https://www.genmabmedicalaffairs.com/sfsites/c/sfc/servlet.shepherd/document/download/069Po00000gYwmAIAS
-
AI radiomic biomarkers, using routine radiology scans, can potentially predict treatment response, assess early progression risk, and characterize response vs resistance mechanisms – improving the understanding of drug response to accelerate clinical development.
-
maybe easier to share the link also for the other AACR 25 posters for epcoritamab, tisotumab and Rina-s
https://www.genmabmedicalaffairs.com/congress?filv1=23 -
Amgen Inc. (AMGN) Q1 2025 Earnings Call Transcript https://conferencecalltranscripts.org/summary/?id=559155&pr=true I would note that within this portfolio, sales of TEPEZZA and KRYSTEXXA were adversely impacted in the quarter by changes to U.S. wholesaler inventory levels. We do not expect similar reductions in inventory levels for the remainder of the year. Since launch, TEPEZZA has had a positive impact for thousands of patients living with thyroid eye disease.
-
In the U.S., there are roughly 100,000 patients suffering from TED who could benefit from TEPEZZA and to reach them, we've intensified our efforts to engage a broad prescriber base of oculoplastic surgeons, ophthalmologists and endocrinologists.
We are encouraged by the feedback that we are receiving from the medical community, including an increase in intent to prescribe reported by endocrinologists during the first quarter.
-
Access has also improved for patients with more than 85% of medical plans, removing clinical activity score requirements. We are advancing our international expansion of TEPEZZA in Japan, TEPEZZA is now the first and only approved therapy for active thyroid eye disease. And in the first full quarter since launch, we've seen strong uptake and positive physician engagement.
-
In the European Union, we are preparing to launch following the recent positive opinion issued by the committee for medicinal products for human use on the approval of TEPEZZA for the treatment of moderate to severe thyroid eye disease in adults. This marks a significant step forward for patients living with TED who currently have no approved disease-modifying therapies available to them in Europe.
-
As Amgen's trio of Horizon drugs disappoint, execs urge analysts to give them more time https://www.fiercepharma.com/pharma/horizon-amgens-sees-better-days-ahead-struggling-tepezza-uplizna
-
Knock-Your-Socks-Off-News – May 2025 https://www.linkedin.com/pulse/knock-your-socks-off-news-may-2025-genmab-a3hlc/
-
Hvornår er ASCO, det plejer at være ca. nu på året... Jeg har ikke fulgt så godt med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind